2021 American Transplant Congress
De-novo Use Comparison Between Extended-release Once-daily Tacrolimus (Envarsus Xr®) and Immediate-release Twice-daily Tacrolimus (Prograf®) – A Single Center’s Experience
*Purpose: Envarsus XR® is approved for de-novo use post-kidney transplantation at a higher starting dose (0.14mg/kg/day) as compared with Prograf® (0.1 mg/kg/day) despite better bioavailability.…2021 American Transplant Congress
Clinical Impact of Transplant Pharmacists on the Care of Solid Organ Transplant Recipients
1Temple University Hospital, Philadelphia, PA, 2Temple School of Pharmacy, Philadelphia, PA
*Purpose: The United Network for Organ Sharing (UNOS) and Centers for Medicare and Medicaid Services (CMS) requires transplant centers to document the participation of a…2021 American Transplant Congress
Valganciclovir Dosing for Cytomegalovirus Prophylaxis in Pediatric Solid Organ Transplant Recipients; Single Center Experience
*Purpose: The main objective of the study is to compare the efficacy of the different Valganciclovir dosing strategies in pediatric solid organ transplant recipients with…2021 American Transplant Congress
Evaluation of Low Dose Famciclovir as Herpes Simplex Virus and Varicella Zoster Virus Prophylaxis in Cytomegalovirus Low Risk Solid Organ Transplant Recipients
Massachusetts General Hospital, Boston, MA
*Purpose: Famciclovir is recommended for herpes simplex virus (HSV) and varicella-zoster virus (VZV) prophylaxis in cytomegalovirus (CMV) low risk (both donor and recipient CMV seronegative)…2021 American Transplant Congress
Evaluation of Conversion to Extended-Release Tacrolimus in Abdominal Organ and Thoracic Transplant Recipients
*Purpose: An established approach for conversion from immediate-release tacrolimus (IR TAC) to extended-release tacrolimus (LCPT) in kidney transplantation exists, but is lacking in other organ…2021 American Transplant Congress
Avoiding Tacrolimus Under- and Overexposure with a Dosing Algorithm for Renal Transplant Recipients: A Single Arm Prospective Intervention Trial
*Purpose: Bodyweight-based tacrolimus dosing followed by therapeutic drug monitoring is standard clinical care after renal transplantation. However, after transplantation, a meagre 38% of patients is…2020 American Transplant Congress
Assessment of Time to Therapeutic Tacrolimus Levels Following Renal Transplantation in a Non-Weight-Based Dosing Model
*Purpose: The optimal initial dose for tacrolimus (TAC) after renal transplant (RT) remains controversial with limited evidence comparing weight-based and conservative strategies. Recent literature suggests…2020 American Transplant Congress
Less Bleeding Associated with Apixaban versus Other Direct Acting Oral Anticoagulation in Solid Organ Transplant Recipients
*Purpose: Owing to their fixed dosing and favorable drug interaction profiles, direct acting oral anticoagulants (DOACs) have supplanted warfarin as the standard of care for…2020 American Transplant Congress
A Single Centre Experience of Conversion from Immediate Release Tacrolimus (IR-tac) to Extended Release Envarsus
*Purpose: IR-Tac is first line maintenance immunosuppression in kidney transplant recipients. Its rapid absorption of 1-2 hours can lead to peak levels (Tmax ) within…2020 American Transplant Congress
Impact of Donor Race on Tacrolimus Dose Requirement for Liver Transplant Recipients
*Purpose: It is well described that there is interpatient variability in tacrolimus dose requirements among transplant recipients. CYP3A5 plays a role in this variability. Black…
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- …
- 9
- Next Page »